Can Remeron or Mirabegron Cause Thirst?
Yes, both mirtazapine (Remeron) and mirabegron can cause thirst, though the mechanisms and evidence quality differ substantially between these medications.
Mirtazapine (Remeron) and Thirst
Mirtazapine is not listed as causing thirst in the FDA drug label 1. The most common side effects documented include sleepiness, increased appetite, weight gain, and dizziness 1. However, mirtazapine can cause dry mouth 2, which may secondarily lead to increased thirst as a compensatory response.
Additionally, a 2024 pharmacovigilance study analyzing the WHO global database identified new safety signals for thirst with several antidepressants, including monoamine reuptake inhibitors like duloxetine and venlafaxine 3. While mirtazapine was not specifically highlighted in this analysis, the drug's anticholinergic properties and its documented association with dry mouth 2 suggest thirst could occur indirectly.
Important caveat: Mirtazapine carries a moderate risk (3.26%) of causing hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH) 4, which paradoxically can present with altered mental status rather than thirst. This typically occurs within 34 days of starting treatment and is more common in elderly females 4.
Mirabegron and Thirst
Mirabegron does not commonly cause thirst based on available evidence. The 2019 AUA/SUFU guideline on overactive bladder discusses mirabegron extensively but does not list thirst as a recognized adverse effect 5.
The most common treatment-emergent adverse events with mirabegron include:
- Hypertension
- Nasopharyngitis
- Urinary tract infection
- Dry mouth (though occurring five times less frequently than with antimuscarinics) 6
Multiple large-scale analyses involving over 8,500 patients found mirabegron to be well-tolerated with adverse event profiles similar to placebo 7, 6, 8, 9. Dry mouth occurs with mirabegron but is significantly less common than with antimuscarinic medications 6, and even this mild anticholinergic effect could theoretically trigger compensatory thirst.
The 2024 WHO pharmacovigilance study did not identify mirabegron as having a safety signal for thirst 3, despite analyzing over 3,000 thirst reports globally.
Clinical Bottom Line
For mirtazapine: Monitor for dry mouth, which may lead to secondary thirst. More importantly, watch for hyponatremia, especially in elderly patients, females, and within the first 5 weeks of treatment.
For mirabegron: Thirst is not an expected side effect. If a patient reports significant thirst on mirabegron, investigate alternative causes including diabetes, other medications, or underlying medical conditions.
Key monitoring: With mirtazapine, check sodium levels if patients develop confusion, weakness, or other neurological symptoms 1, 4. With mirabegron, monitor blood pressure, as small increases (0.4-0.6 mmHg) can occur 6.